Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiometabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PCSK9 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild Type) | PCSK9 Full-Length / ECD-Fc Fusion; High purity (>95%), Endotoxin <1 EU/µg; Sequence Verified; HEK293 Expressed (Native Glycosylation). | View PCSK9 Products |
| Antigen (Mutant) | PCSK9 D374Y Gain-of-Function Mutant; Theoretical MW verified; also available: R218S mutant for epitope breadth screening. | View PCSK9 Products |
| Gene Delivery | PCSK9 Promise-ORF / Lentivirus Premade Particles; Full-length ORF for stable HepG2 cell line construction; Endotoxin Controlled. | View PCSK9 Products |
| Benchmark Ab (Evolocumab) | Anti-PCSK9 (Sequence of Evolocumab); Recombinant human IgG2 positive control; Sequence Verified. | View PCSK9 Products |
| Benchmark Ab (Alirocumab) | Anti-PCSK9 (Sequence of Alirocumab); Recombinant human IgG1 positive control; Sequence Verified. | View PCSK9 Products |
| Validator | PCSK9 siRNA Set (3 targets + control); For knockdown verification and specificity controls. | View PCSK9 Products |
| Binding Partner | LDLR ECD Protein; EGF-A domain containing; For competition binding assays (PCSK9-LDLR disruption). | View LDLR Products |
| Related Target | ANGPTL3; Complementary lipid pathway target; For combination therapy screening. | View ANGPTL3 Products |
| Related Target | APOC3; Triglyceride metabolism node; For cardiometabolic panel screening. | View APOC3 Products |
| Related Target | HMGCR; Statin synergy target; MoA comparison and combination studies. | View HMGCR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval (Preclinical translation) | Human/Mouse/Cyno ortholog proteins available with >95% purity; Sequence Verified by Mass Spec. |
| Subfamily selectivity (Avoiding Furin/PC5/6 off-target) | Strict homolog panel available (Furin, PC5/6, PACE4) for counter-screening; High purity antigens. |
| Gain-of-function mechanism validation | D374Y Mutant Protein (Theoretical MW matched) and R218S mutant for enhanced LDLR binding assays. |
| Lack of assay controls | Clinical Benchmark Antibodies (Evolocumab/Alirocumab Biosimilar sequences) included. |
| False positive binding (Specificity verification) | Validated siRNA included for PCSK9 knockdown specificity checks in cellular LDL uptake assays. |
Live PCSK9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The PCSK9 therapeutic landscape has matured beyond injectable monoclonal antibodies into a diversified ecosystem encompassing siRNA-mediated gene silencing (Inclisiran), oral cyclic peptides (Merck's MK-0616), and in vivo gene editing (Verve Therapeutics' VERVE-101). As first-generation biologics establish market presence, the next wave of R&D prioritizes patient convenience through oral bioavailability and one-time curative interventions via base editing. The convergence of LDL-lowering therapies with triglyceride-targeting agents (ANGPTL3/APOC3) indicates a strategic shift toward combination regimens for residual cardiovascular risk. Future competitive differentiation will hinge on dosing frequency, route of administration, and the ability to cover gain-of-function mutations (e.g., D374Y) prevalent in familial hypercholesterolemia.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Amgen (Evolocumab), Regeneron/Sanofi (Alirocumab) | Hypercholesterolemia, CVD Prevention | High-affinity SPR/BLI characterization; Cyno cross-reactivity for toxicology (Need Human/Cyno PCSK9) |
| siRNA | Novartis (Inclisiran) | Atherosclerotic CVD | Intracellular delivery validation; Endosomal escape assays (Need stable cell line via Lentivirus) |
| Oral Small Molecule/Cyclic Peptide | Merck (MK-0616), Multiple Biotechs | HeFH, Statin-intolerant patients | Cell permeability & LDL uptake functional assay (Need HepG2 stable line overexpressing PCSK9) |
| Gene Editing (Base Editing) | Verve Therapeutics (VERVE-101), Beam Therapeutics | Homozygous Familial Hypercholesterolemia | On-target specificity screening; Off-target proprotein convertase analysis (Need homolog panel) |
| Bispecific / Combo | Research Phase | Residual risk (LDL + TG) | Dual target engagement (Need PCSK9 + ANGPTL3 co-expression systems) |
Molecular Differentiation & Assay Strategy
To achieve best-in-class status, candidates must excel in:
- Affinity & Kinetics – Slow off-rate to prolong target occupancy; epitope must block PCSK9-LDLR interaction (D374 region). Assay: SPR/BLI competition with Evolocumab/Alirocumab control.
- Cross-species Reactivity – Essential for toxicology (cyno) and efficacy (mouse). Use ortholog panel for binding validation.
- Subfamily Selectivity – Avoid off-target binding to Furin/PC5/6/PACE4. Counter-screen with strict homolog panel.
- Functional Validation – Demonstrate rescue of LDLR degradation in HepG2 cells via LDL uptake assay; use PCSK9 siRNA as positive knockdown control.
- Mutant Coverage – Verify activity against gain-of-function mutants (D374Y, R218S) prevalent in familial hypercholesterolemia patients.
TarMart provides high-purity, sequence-verified reagents for each of these dimensions, including wild-type and mutant antigens, ortholog proteins, benchmark antibodies, lentiviral particles, and siRNA sets.